Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J Hepatol 2014; 6(5): 326-339 [PMID: 24868326 DOI: 10.4254/wjh.v6.i5.326]
Corresponding Author of This Article
Igor Bakulin, MD, PhD, Chief of the Department of Hepatology, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 86, Entuziastov highway, 111123 Moscow, Russia. passetchnikov@mail.ru
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2014; 6(5): 326-339 Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety
Igor Bakulin, Victor Pasechnikov, Anna Varlamicheva, Irina Sannikova
Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia
Victor Pasechnikov, Irina Sannikova, Stavropol State Medical University, 355020 Stavropol, Russia
Author contributions: Bakulin I, Pasechnikov V, Varlamicheva A and Sannikova I analyzed publications and results of clinical trials; Varlamicheva A and Sannikova I wrote the manuscript; Bakulin I and Pasechnikov V corrected the manuscript and modified the language.
Correspondence to: Igor Bakulin, MD, PhD, Chief of the Department of Hepatology, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 86, Entuziastov highway, 111123 Moscow, Russia. passetchnikov@mail.ru
Telephone: +7-925-5186538 Fax: +7-499-3720023
Received: November 2, 2013 Revised: February 8, 2014 Accepted: April 11, 2014 Published online: May 27, 2014
Abstract
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.
Core tip: This article reviews NS3/4A protease inhibitors, focusing on major criteria such as effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of protease inhibitor administered in clinical settings.
